DAY
9-11
Treatment with Liposomal Amphotericin B and
voriconazole was initiated*
Due to the severity of Fatima's condition, a craniotomy
was performed, and when Rhizopus was detected in the
surgical sample, treatment was started with Liposomal
Amphotericin B (5 mg/kg/day)** and voriconazole
(400 mg bid on the first day and then 200 mg bid
thereafter). Subsequently, antibiotics were added for
possible nocardiosis based on initial imaging.
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually instituted at a daily dose of 1.0 mg/kg of body weight and increased stepwise to
3.0 mg/kg as required. Data are presently insufficient to define total dosage requirements and duration
of treatment necessary for resolution of mycoses. Dosage of amphotericin B as Liposomal Amphotericin B
 must be adjusted to the specific requirements of each patient.11
During the craniotomy, part of the mass was
removed.
After two days of treatment, there was no
improvement in Fatima’s neurological status.
A repeat cerebral CT was ordered.
Why Liposomal Amphotericin B
Decision point
Results
DAY
9-11
Treatment with Liposomal Amphotericin B and
voriconazole was initiated*
Due to the severity of Fatima's condition, a craniotomy was performed, and when Rhizopus was
detected in the surgical sample, treatment was started with Liposomal Amphotericin B
(5 mg/kg/day)** and voriconazole (400 mg bid on the first day and then 200 mg bid thereafter).
Subsequently, antibiotics were added for possible nocardiosis based on initial imaging.
During the craniotomy, part of the mass was removed.
After two days of treatment, there was no improvement in Fatima’s neurological status.
A repeat cerebral CT was ordered.
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment. Therapy is usually instituted at a daily dose of 1.0 mg/kg of body weight and increased stepwise to
3.0 mg/kg as required. Data are presently insufficient to define total dosage requirements and duration of treatment necessary for resolution of mycoses. Dosage of amphotericin B as
Liposomal Amphotericin B must be adjusted to the specific requirements of each patient.11
Decision point
Why Liposomal Amphotericin B
Results